Welcome!

News Feed Item

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2012

NEW YORK, Nov. 13, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2012

http://www.reportlinker.com/p0332347/Partnerships-Licensing-Investments-...

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2012

Summary

GlobalData derived the data presented in this report from proprietary in-house deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena. - Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.- Analysis of partnership and licensing deals based on clinical stage of development of products.-

Summary

of the pharmaceutical deals globally in the last five quarters.- Information on the top deals happened in the pharmaceutical industry.- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.- Find out the major deal performing segments for investments in your industry.- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.- Identify companies that are aggressively looking to raise capital in the market- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.- Identify growth segments and opportunities in each region within the industry.- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.1 Table of Contents1 Table of Contents 21.1 List of Tables 41.2 List of Figures 62 Industry Insights 83 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2012 93.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2012 93.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2012 113.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2012 123.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2012 133.4.1 Aetna to Acquire Coventry Health Care, Provider of Healthcare Services, for up to $7.3 Billion 133.4.2 WellPoint Extends Antitrust Clearance Approval to Acquire Amerigroup for $4.9 Billion 143.4.3 Linde Completes Acquisition of Lincare, Provider of Respiratory Therapy Services, for $4.6 Billion 143.4.4 Valeant Pharma to Acquire Medicis Pharma, Developer of Treatment for Dermatology and Aesthetics Conditions, for up To $2.6 Billion 143.4.5 Health Care REIT to Acquire Sunrise Senior Living for $1.9 Billion 154 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 164.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2012 164.1.1 Top M&A Deals in Q3 2012 174.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2011 - Q3 2012 184.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2012 194.2.1 Top Initial Public Offerings in Q3 2012 204.2.2 Top Secondary Offerings in Q3 2012 204.2.3 Top PIPE Deals in Q3 2012 204.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2011–Q3 2012 214.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2011 – Q3 2012 224.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2012 234.3.1 Top Venture Financing Deals in Q3 2012 244.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2012 244.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2012 254.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2011 - Q3 2012 264.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 274.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 284.3.7 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2012 294.3.8 Top Private Equity Deals in Q3 2012 304.3.9 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2011 - Q3 2012 315 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2012 325.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2012 325.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2011 - Q3 2012 345.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 355.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2012 365.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2012 365.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2012 375.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 385.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2011 - Q3 2012 395.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2011 - Q3 2012 405.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 416 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2012 426.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2012 426.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 436.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2012 446.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2012 446.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2012 456.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2011 - Q3 2012 466.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2011 - Q3 2012 476.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2011 - Q3 2012 486.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2011 - Q3 2012 496.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2011 - Q3 2012 507 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 517.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q3 2011 - Q3 2012 517.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q3 2011 - Q3 2012 527.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2011 - Q3 2012 537.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2011 - Q3 2012 547.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q3 2011 - Q3 2012 557.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q3 2011 - Q3 2012 567.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2011 - Q3 2012 578 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 588.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2012 588.1.1 Oncology – Deals of the Quarter 598.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2012 618.2.1 Central Nervous System – Deals of the Quarter 628.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2012 638.3.1 Infectious Disease – Deals of the Quarter 648.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2012 658.4.1 Immunology – Deals of the Quarter 668.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2012 688.5.1 Metabolic Disorders – Deals of the Quarter 698.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2012 708.6.1 Cardiovascular – Deals of the Quarter 718.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2012 728.7.1 Gastrointestinal – Deals of the Quarter 738.8 Pharmaceuticals & Healthcare, Global, Hematological Disorders Deals, Q3 2012 748.8.1 Hematological Disorders – Deals of the Quarter 758.9 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2012 778.9.1 Dermatology – Deals of the Quarter 788.10 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2012 798.10.1 Respiratory – Deals of the Quarter 809 Deal Summary by Geography 819.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2012 819.1.1 North America – Deals of the Quarter 829.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2012 839.2.1 Europe – Deals of the Quarter 849.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2012 859.3.1 Asia-Pacific – Deals of the Quarter 869.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2012 889.4.1 Rest of the World – Deals of the Quarter 8910 Pharmaceuticals & Healthcare, Global, Top Advisors 9010.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 9010.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 9111 Appendix 9212 Further Information 9612.1 Methodology 9612.2 About GlobalData 9612.3 Contact Us 9712.4 Disclosure information 9712.5 Disclaimer 97

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 10Table 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (%), Q3 2012 12Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2012 13Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 – Q3 2012 17Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2012 17Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2011 - Q3 2012 18Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 19Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2012 20Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2012 20Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2012 20Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q3 2011–Q3 2012 21Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 22Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 23Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2012 24Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2012 25Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 26Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2011 – Q3 2012 27Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q4 2011 – Q3 2012 28Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 – Q3 2012 29Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2012 30Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 31Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 33Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 34Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 35Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2012 36Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2012 36Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2012 37Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 38Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012 40Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 41Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 42Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 43Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2012 44Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2012 44Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2012 45Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 46Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2011 - Q3 2012 47Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012 49Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 50Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2011 - Q3 2012 51Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2011 - Q3 2012 52Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2011 - Q3 2012 53Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q3 2011 - Q3 2012 54Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2009 - Q3 2012 55Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2011 - Q3 2012 56Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2011 - Q3 2012 57Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 59Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 62Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 64Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 66Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 69Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 70Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 73Table 54: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 75Table 55: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 78Table 56: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 80Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 82Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 84Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 86Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 89Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012 90Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012 91Table 63: Pharmaceuticals & Healthcare, Deals' Key Financials, Global Acquisition Deals, Q3 2011-Q3 2012 92

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 9Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals (%), Q3 2012 11Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2012 12Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2011 - Q3 2012 16Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2011 – Q3 2012 18Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 19Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), , Q3 2011 – Q3 2012 22Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 23Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2012 24Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2012 25Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2011 - Q3 2012 26Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q4 2011 – Q3 2012 27Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2011 – Q3 2012 29Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2011 - Q3 2012 31Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 32Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 34Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 35Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 38Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012 39Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2011 - Q3 2012 40Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 41Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 42Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2011 - Q3 2012 43Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 46Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 47Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2011 - Q3 2012 48Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2011 - Q3 2012 49Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2011 - Q3 2012 50Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q3 2011 - Q3 2012 51Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q3 2011 - Q3 2012 52Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q3 2011 - Q3 2012 53Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q3 2011 – Q3 2012 54Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q3 2011 - Q3 2012 55Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q3 2011 - Q3 2012 56Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q3 2011 - Q3 2012 57Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 58Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 61Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 63Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 65Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 68Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 70Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 72Figure 43: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 74Figure 44: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 77Figure 45: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 79Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 81Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 83Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 85Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2011 - Q3 2012 88Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012 90Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q4 2011 - Q3 2012 91

Companies Mentioned

To order this report:Investment_Banking Industry: Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2012

Contact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Peak 10, Inc., a national IT infrastructure and cloud services provider, will exhibit at SYS-CON's 18th International Cloud Expo®, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. Peak 10 provides reliable, tailored data center and network services, cloud and managed services. Its solutions are designed to scale and adapt to customers’ changing business needs, enabling them to lower costs, improve performance and focus inter...
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
If there is anything we have learned by now, is that every business paves their own unique path for releasing software- every pipeline, implementation and practices are a bit different, and DevOps comes in all shapes and sizes. Software delivery practices are often comprised of set of several complementing (or even competing) methodologies – such as leveraging Agile, DevOps and even a mix of ITIL, to create the combination that’s most suitable for your organization and that maximize your busines...
Struggling to keep up with increasing application demand? Learn how Platform as a Service (PaaS) can streamline application development processes and make resource management easy.
In his session at @ThingsExpo, Chris Klein, CEO and Co-founder of Rachio, will discuss next generation communities that are using IoT to create more sustainable, intelligent communities. One example is Sterling Ranch, a 10,000 home development that – with the help of Siemens – will integrate IoT technology into the community to provide residents with energy and water savings as well as intelligent security. Everything from stop lights to sprinkler systems to building infrastructures will run ef...
Whether your IoT service is connecting cars, homes, appliances, wearable, cameras or other devices, one question hangs in the balance – how do you actually make money from this service? The ability to turn your IoT service into profit requires the ability to create a monetization strategy that is flexible, scalable and working for you in real-time. It must be a transparent, smoothly implemented strategy that all stakeholders – from customers to the board – will be able to understand and comprehe...
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, will discuss how research has demonstrated the value of Machine Learning in delivering next generation analytics to im...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists will dis...
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
Unless you don’t use the internet, don’t live in California, or haven’t been paying attention to the recent news… you should be aware that self-driving cars are on their way to becoming a reality. I have seen them – they are real. If you believe in the future reality of self-driving cars, then continue reading on. If you don’t believe in the future possibilities, then I am not sure what to do to convince you other than discuss the very real changes that will roll out with the consumer producti...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
There is an ever-growing explosion of new devices that are connected to the Internet using “cloud” solutions. This rapid growth is creating a massive new demand for efficient access to data. And it’s not just about connecting to that data anymore. This new demand is bringing new issues and challenges and it is important for companies to scale for the coming growth. And with that scaling comes the need for greater security, gathering and data analysis, storage, connectivity and, of course, the...
This is not a small hotel event. It is also not a big vendor party where politicians and entertainers are more important than real content. This is Cloud Expo, the world's longest-running conference and exhibition focused on Cloud Computing and all that it entails. If you want serious presentations and valuable insight about Cloud Computing for three straight days, then register now for Cloud Expo.
IoT device adoption is growing at staggering rates, and with it comes opportunity for developers to meet consumer demand for an ever more connected world. Wireless communication is the key part of the encompassing components of any IoT device. Wireless connectivity enhances the device utility at the expense of ease of use and deployment challenges. Since connectivity is fundamental for IoT device development, engineers must understand how to overcome the hurdles inherent in incorporating multipl...